Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination
Pathogens · 2026
DOI: 10.3390/pathogens15020157 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathogens, 2026. Verfasst von Wendong Gu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan. Hauptthemen laut MEDLINE: Herpesvirus 3, Human, Herpes Zoster Ophthalmicus, Varicella Zoster Virus Infection, Eye Infections, Viral. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 123 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Ministry of Health, Labour, and Welfare of Japan, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Varicella-Zoster Virus (VZV) is one of the most important pathogens in ophthalmology. Reactivation may involve the adnexa (blepharoconjunctivitis, pseudomembranous conjunctivitis), cornea (dendritic keratitis, nummular and necrotizing stromal keratitis, disciform endotheliitis, neurotrophic ulcers, mucous-plaque keratitis) and sclera (episcleritis, anterior scleritis). Uveal inflammation ranges from anterior uveitis—with iris atrophy, trabeculitis-induced glaucoma and complicated cataract—to posterior necrotizing syndromes: acute retinal necrosis in immunocompetent hosts and progressive outer retinal necrosis in immunosuppressed patients, often complicated by occlusive vasculitis, macular edema, retinal detachment and phthisis. Optic nerve and cranial nerve involvement (optic neuritis, neuroretinitis, III/IV/VI palsies) and orbital inflammation may occur even without cutaneous signs (“zoster sine herpete”), making PCR-based intraocular diagnostics essential. Management relies on early, high-dose antivirals (acyclovir or valacyclovir), judicious corticosteroids and timely surgical intervention when required. Universal childhood varicella vaccination and recombinant zoster vaccination in adults ≥50 years have reduced VZV incidence and ocular complications in settings with high vaccine coverage, though rare post-vaccine keratitis or uveitis underscore the need for ongoing vigilance. In this review, we synthesize current knowledge on varicella-zoster virus ocular disease, with a focus on host–pathogen interactions that drive both injury and defense.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology & Visual Science, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan.
- Department of Ophthalmology, Zhongshan Torch Development Zone People's Hospital, Zhongshan 528436, China.
ORCID-Profile: Wendong Gu, Yaru Zou, Jing Zhang
Förderung
- JSPS KAKENHI
- Ministry of Health, Labour, and Welfare of Japan
- Japan Agency for Medical Research and Development
- Takeda Science Foundation
- Japan Agency for Medical Research and Development, AMED
Zitieren
APA
Gu, W., Zou, Y., Yang, M., Zhang, J., Ye, Z., Deng, J., Zong, Y., Ohno-Matsui, K., & Kamoi, K. (2026). Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination. Pathogens. https://doi.org/10.3390/pathogens15020157
Vancouver
Gu W, Zou Y, Yang M, Zhang J, Ye Z, Deng J, et al. Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination. Pathogens. 2026. doi:10.3390/pathogens15020157
BibTeX
@article{Gu2026,
author = {Gu, Wendong and Zou, Yaru and Yang, Mingming and Zhang, Jing and Ye, Zizhen and Deng, Jiaxin and Zong, Yuan and Ohno-Matsui, Kyoko and Kamoi, Koju},
title = {Varicella-Zoster Virus and the Eye: Clinical Spectrum, Management, and Vaccination},
journal = {Pathogens},
year = {2026},
doi = {10.3390/pathogens15020157}
}
EUVIMED